SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-049106
Filing Date
2020-02-26
Accepted
2020-02-26 07:10:44
Documents
14
Period of Report
2020-02-26
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d848593d8k.htm   iXBRL 8-K 27795
2 EX-99.1 d848593dex991.htm EX-99.1 605085
6 GRAPHIC g848593horizon.jpg GRAPHIC 2657
  Complete submission text file 0001193125-20-049106.txt   815295

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA hznp-20200226.xsd EX-101.SCH 3084
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE hznp-20200226_lab.xml EX-101.LAB 18839
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE hznp-20200226_pre.xml EX-101.PRE 11848
15 EXTRACTED XBRL INSTANCE DOCUMENT d848593d8k_htm.xml XML 3603
Mailing Address CONNAUGHT HOUSE, 1ST FLOOR 1 BURLINGTON ROAD DUBLIN L2 4
Business Address CONNAUGHT HOUSE, 1ST FLOOR 1 BURLINGTON ROAD DUBLIN L2 4 011-353-1-772-2100
Horizon Therapeutics Public Ltd Co (Filer) CIK: 0001492426 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35238 | Film No.: 20653283
SIC: 2834 Pharmaceutical Preparations